Have any questions? 706-721-6582 or cts@augusta.edu
- CLR_15_03: A Two-Part Phase 1/2 Study to Determine Safety, Tolerability, Pharmacokinetics, and Activity of K0706, a Novel Tyrosine Kinase Inhibitor (TKI), in Healthy Subjects and in Subjects with Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
Clinical Trial
CLR_15_03: A Two-Part Phase 1/2 Study to Determine Safety, Tolerability, Pharmacokinetics, and Activity of K0706, a Novel Tyrosine Kinase Inhibitor (TKI), in Healthy Subjects and in Subjects with Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
Patients are being asked to take part in this study because they have Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL). Our site is participating in the Phase 2 portion of the study. The purpose of the Phase 2 portion of the study is to examine the effects of the study drug on a small group of patients with chronic myeloid leukemia (CML). This study will allow us to learn more about how safe and effective the study drug is before it can be considered for approval as a prescription drug by the FDA.
Eligibility Criteria
- Male or female, aged 18 years or older Subjects with confirmed chronic myeloid leukemia (CML) Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures
RESEARCH. INNOVATION. DISCOVERY.